Increased Oxidative Damage and Decreased Antioxidant Function in Aging Human Substantia Nigra Compared to Striatum: Implications for Parkinson’s Disease
- C. Venkateshappa,
- G. Harish,
- Rajeswara Babu Mythri,
- Anita Mahadevan,
- M. M. Srinivas Bharath,
- S. K. Shankar
- … show all 6 hide
Purchase on Springer.com
$39.95 / €34.95 / £29.95 *
* Final gross prices may vary according to local VAT.
Abstract
Parkinson’s disease (PD) is characterized by selective degeneration and loss of dopaminergic neurons in the substantia nigra (SN) of the ventral mid brain leading to dopamine depletion in the striatum. Oxidative stress and mitochondrial damage have been implicated in the death of SN neurons during the evolution of PD. In our previous study on human PD brains, we observed that compared to SN, striatum was significantly protected against oxidative damage and mitochondrial dysfunction. To understand whether brain aging contributes to the vulnerability of midbrain to neurodegeneration in PD compared to striatum, we assessed the status of oxidant and antioxidant markers, glutathione metabolic enzymes, glial fibrillary acidic protein (GFAP) expression and mitochondrial complex I(CI) activity in SN (n = 23) and caudate nucleus (n = 24) during physiological aging in human brains. We observed a significant increase in protein oxidation (P < 0.001), loss of CI activity (P = 0.04) and increased astrocytic proliferation indicated by GFAP expression (P < 0.001) in SN compared to CD with increasing age. These changes were attributed to significant decrease in antioxidant function represented by superoxide dismutase (SOD) (P = 0.03), glutathione (GSH) peroxidase (GPx) (P = 0.02) and GSH reductase (GR) (P = 0.03) and a decreasing trend in total GSH and catalase with increasing age. However, these parameters were relatively unaltered in CD. We propose that SN undergoes extensive oxidative damage, loss of antioxidant and mitochondrial function and increased GFAP expression during physiological aging which might make it more vulnerable to neurotoxic insults thus contributing to selective degeneration during evolution of PD.
Look
Inside
Within this Article
- Introduction
- Experimental Procedure
- Results
- Discussion
- References
- References
Related Content
Supplementary Material (0)
References (78)
- Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17:427–442
- Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211 CrossRef
- Adams JD Jr, Chang ML, Klaidman L (2001) Parkinson’s disease—redox mechanisms. Curr Med Chem 8:809–814
- Beal MF (1992) Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann Neurol 31:119–130. doi:10.1002/ana.410310202 CrossRef
- Jenner P, Dexter DT, Sian J, Schapira AH, Marsden CD (1992) Oxidative stress as a cause of nigral cell death in Parkinson’s disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson’s Disease Research Group. Ann Neurol 32(Suppl):S82–S87 CrossRef
- Koiliatsos VE (1998) Parkinson’s disease. In: Burke RE (ed) Cell death and disease of the nervous system. Humana Press, Totowa, pp 459–475
- Sayre LM, Smith MA, Perry G (2001) Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Curr Med Chem 8:721–738
- Dexter DT, Wells FR, Lees AJ, Agid F, Agid Y, Jenner P, Marsden CD (1989) Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson’s disease. J Neurochem 52:1830–1836 CrossRef
- Sofic E, Paulus W, Jellinger K, Riederer P, Youdim MB (1991) Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem 56:978–982 CrossRef
- Bharath S, Hsu M, Kaur D, Rajagopalan S, Andersen JK (2002) Glutathione, iron and Parkinson’s disease. Biochem Pharmacol 64:1037–1048 CrossRef
- Alam ZI, Daniel SE, Lees AJ, Marsden DC, Jenner P, Halliwell B (1997) A generalised increase in protein carbonyls in the brain in Parkinson’s but not incidental Lewy body disease. J Neurochem 69:1326–1329 CrossRef
- Floor E, Wetzel MG (1998) Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J Neurochem 70:268–275 CrossRef
- Good PF, Hsu A, Werner P, Perl DP, Olanow CW (1998) Protein nitration in Parkinson’s disease. J Neuropathol Exp Neurol 57:338–342 CrossRef
- Blanchard-Fillion B, Prou D, Polydoro M, Spielberg D, Tsika E, Wang Z, Hazen SL, Koval M, Przedborski S, Ischiropoulos H (2006) Metabolism of 3-nitrotyrosine induces apoptotic death in dopaminergic cells. J Neurosci 26:6124–6130. doi:10.1523/JNEUROSCI.1038-06.2006 CrossRef
- Danielson SR, Andersen JK (2008) Oxidative and nitrative protein modifications in Parkinson’s disease. Free Radic Biol Med 44:1787–1794. doi:10.1016/j.freeradbiomed.2008.03.005 CrossRef
- Ferrante RJ, Hantraye P, Brouillet E, Beal MF (1999) Increased nitrotyrosine immunoreactivity in substantia nigra neurons in MPTP treated baboons is blocked by inhibition of neuronal nitric oxide synthase. Brain Res 823:177–182 CrossRef
- Hasegawa E, Takeshige K, Oishi T, Murai Y, Minakami S (1990) 1-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles. Biochem Biophys Res Commun 170:1049–1055 CrossRef
- Ischiropoulos H, Beckman JS (2003) Oxidative stress and nitration in neurodegeneration: cause, effect, or association? J Clin Invest 111:163–169
- Pennathur S, Jackson-Lewis V, Przedborski S, Heinecke JW (1999) Mass spectrometric quantification of 3-nitrotyrosine, ortho-tyrosine, and o, o′-dityrosine in brain tissue of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice, a model of oxidative stress in Parkinson’s disease. J Biol Chem 274:34621–34628 CrossRef
- Keeney PM, Xie J, Capaldi RA, Bennett JP Jr (2006) Parkinson’s disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J Neurosci 26:5256–5264. doi:10.1523/JNEUROSCI.0984-06.2006 CrossRef
- Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD (1990) Mitochondrial complex I deficiency in Parkinson’s disease. J Neurochem 54:823–827 CrossRef
- Rogers J, Mastroeni D, Leonard B, Joyce J, Grover A (2007) Neuroinflammation in Alzheimer’s disease and Parkinson’s disease: are microglia pathogenic in either disorder? Int Rev Neurobiol 82:235–246 CrossRef
- Werner CJ, Heyny-von Haussen R, Mall G, Wolf S (2008) Proteome analysis of human substantia nigra in Parkinson’s disease. Proteome Sci 6:8 CrossRef
- Mythri RB, Venkateshappa C, Harish G, Mahadevan A, Muthane UB, Yasha TC, Srinivas Bharath MM, Shankar SK (2011) Evaluation of markers of oxidative stress, antioxidant function and astrocytic proliferation in the striatum and frontal cortex of Parkinson’s disease brains. Neurochem Res 36:1452–1463. doi:10.1007/s11064-011-0471-9 CrossRef
- Karunakaran S, Saeed U, Ramakrishnan S, Koumar RC, Ravindranath V (2007) Constitutive expression and functional characterization of mitochondrial glutaredoxin (Grx2) in mouse and human brain. Brain Res 1185:8–17. doi:10.1016/j.brainres.2007.09.019 CrossRef
- Karunakaran S, Saeed U, Mishra M, Valli RK, Joshi SD, Meka DP, Seth P, Ravindranath V (2008) Selective activation of p38 mitogen-activated protein kinase in dopaminergic neurons of substantia nigra leads to nuclear translocation of p53 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice. J Neurosci 28:12500–12509. doi:10.1523/jneurosci.4511-08.2008 CrossRef
- Alladi PA, Mahadevan A, Yasha TC, Raju TR, Shankar SK, Muthane U (2009) Absence of age-related changes in nigral dopaminergic neurons of Asian Indians: relevance to lower incidence of Parkinson’s disease. Neuroscience 159:236–245. doi:10.1016/j.neuroscience.2008.11.051 CrossRef
- Chinta SJ, Kommaddi RP, Turman CM, Strobel HW, Ravindranath V (2005) Constitutive expression and localization of cytochrome P-450 1A1 in rat and human brain: presence of a splice variant form in human brain. J Neurochem 93:724–736. doi:10.1111/j.1471-4159.2005.03061.x CrossRef
- Agarwal V, Kommaddi RP, Valli K, Ryder D, Hyde TM, Kleinman JE, Strobel HW, Ravindranath V (2008) Drug metabolism in human brain: high levels of cytochrome P4503A43 in brain and metabolism of anti-anxiety drug alprazolam to its active metabolite. PLoS One 3:e2337. doi:10.1371/journal.pone.0002337 CrossRef
- Chandana R, Mythri RB, Mahadevan A, Shankar SK, Srinivas Bharath MM (2009) Biochemical analysis of protein stability in human brain collected at different post-mortem intervals. Indian J Med Res 129:189–199
- Alladi PA, Mahadevan A, Shankar SK, Raju TR, Muthane U (2010) Expression of GDNF receptors GFRalpha1 and RET is preserved in substantia nigra pars compacta of aging Asian Indians. J Chem Neuroanat 40:43–52. doi:10.1016/j.jchemneu.2010.03.007 CrossRef
- Alladi PA, Mahadevan A, Vijayalakshmi K, Muthane U, Shankar SK, Raju TR (2010) Ageing enhances alpha-synuclein, ubiquitin and endoplasmic reticular stress protein expression in the nigral neurons of Asian Indians. Neurochem Int 57:530–539. doi:10.1016/j.neuint.2010.06.018 CrossRef
- Jagatha B, Mythri RB, Vali S, Bharath MM (2008) Curcumin treatment alleviates the effects of glutathione depletion in vitro and in vivo: therapeutic implications for Parkinson’s disease explained via in silico studies. Free Radic Biol Med 44:907–917. doi:10.1016/j.freeradbiomed.2007.11.011 CrossRef
- Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351–358 CrossRef
- Aebi H (1984) Catalase in vitro. Methods Enzymol 105:121–126 CrossRef
- Bagnyukova TV, Storey KB, Lushchak VI (2003) Induction of oxidative stress in Rana ridibunda during recovery from winter hibernation. J Therm Biol 28:21–28 CrossRef
- Tietze F (1969) Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem 27:502–522 CrossRef
- Flohe L, Gunzler WA (1984) Assays of glutathione peroxidase. Methods Enzymol 105:114–121 CrossRef
- Carlberg I, Mannervik B (1985) Glutathione reductase. Methods Enzymol 113:484–490 CrossRef
- Guthenberg C, Alin P, Mannervik B (1985) Glutathione transferase from rat testis. Methods Enzymol 113:507–510 CrossRef
- Mythri RB, Jagatha B, Pradhan N, Andersen J, Bharath MM (2007) Mitochondrial complex I inhibition in Parkinson’s disease: how can curcumin protect mitochondria? Antioxid Redox Signal 9:399–408. doi:10.1089/ars.2007.9.ft-25 CrossRef
- Trounce IA, Kim YL, Jun AS, Wallace DC (1996) Assessment of mitochondrial oxidative phosphorylation in patient muscle biopsies, lymphoblasts, and transmitochondrial cell lines. Methods Enzymol 264:484–509 CrossRef
- Albers DS, Beal MF (2000) Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease. J Neural Transm Suppl 59:133–154
- Banerjee R, Starkov AA, Beal MF, Thomas B (2009) Mitochondrial dysfunction in the limelight of Parkinson’s disease pathogenesis. Biochim Biophys Acta 1792:651–663. doi:10.1016/j.bbadis.2008.11.007
- Lin MT, Beal MF (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443:787–795. doi:10.1038/nature05292 CrossRef
- Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD (1989) Mitochondrial complex I deficiency in Parkinson’s disease. Lancet 1:1269 CrossRef
- Damier P, Hirsch EC, Zhang P, Agid Y, Javoy-Agid F (1993) Glutathione peroxidase, glial cells and Parkinson’s disease. Neuroscience 52:1–6 CrossRef
- Jenner P (1993) Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson’s disease. Acta Neurol Scand 146(Suppl):6–13
- Kolosova NG, Shcheglova TV, Amstislavskaya TG, Loskutova LV (2003) Comparative analysis of LPO products in brain structures of Wistar and OXYS rats of different age. Bull Exp Biol Med 135:593–596 CrossRef
- Mizuno Y, Ohta K (1986) Regional distributions of thiobarbituric acid-reactive products, activities of enzymes regulating the metabolism of oxygen free radicals, and some of the related enzymes in adult and aged rat brains. J Neurochem 46:1344–1352 CrossRef
- Anglade P, Vyas S, Hirsch EC, Agid Y (1997) Apoptosis in dopaminergic neurons of the human substantia nigra during normal aging. Histol Histopathol 12:603–610
- Surmeier DJ, Guzman JN, Sanchez-Padilla J, Goldberg JA (2011) The origins of oxidant stress in Parkinson’s disease and therapeutic strategies. Antioxid Redox Signal 14:1289–1301. doi:10.1089/ars.2010.3521 CrossRef
- Double KL, Reyes S, Werry EL, Halliday GM (2010) Selective cell death in neurodegeneration: why are some neurons spared in vulnerable regions? Prog Neurobiol 92:316–329. doi:10.1016/j.pneurobio.2010.06.001 CrossRef
- Waters CM, Peck R, Rossor M, Reynolds GP, Hunt SP (1988) Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson’s disease and Huntington’s chorea. Neuroscience 25:419–438 CrossRef
- Kish SJ, Shannak K, Rajput A, Deck JH, Hornykiewicz O (1992) Aging produces a specific pattern of striatal dopamine loss: implications for the etiology of idiopathic Parkinson’s disease. J Neurochem 58:642–648 CrossRef
- Riederer BM (1989) Antigen preservation tests for immunocytochemical detection of cytoskeletal proteins: influence of aldehyde fixatives. J Histochem Cytochem 37:675–681 CrossRef
- Sofic E, Lange KW, Jellinger K, Riederer P (1992) Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson’s disease. Neurosci Lett 142:128–130 CrossRef
- Frade J, Pope S, Schmidt M, Dringen R, Barbosa R, Pocock J, Laranjinha J, Heales S (2008) Glutamate induces release of glutathione from cultured rat astrocytes—a possible neuroprotective mechanism? J Neurochem 105:1144–1152. doi:10.1111/j.1471-4159.2008.05216.x CrossRef
- Mann VM, Cooper JM, Daniel SE, Srai K, Jenner P, Marsden CD, Schapira AH (1994) Complex I, iron, and ferritin in Parkinson’s disease substantia nigra. Ann Neurol 36:876–881. doi:10.1002/ana.410360612 CrossRef
- Ciriolo MR, Fiskin K, De Martino A, Corasaniti MT, Nistico G, Rotilio G (1991) Age-related changes in Cu, Zn superoxide dismutase, Se-dependent and -independent glutathione peroxidase and catalase activities in specific areas of rat brain. Mech Ageing Dev 61:287–297 CrossRef
- Carrillo MC, Kanai S, Sato Y, Kitani K (1992) Age-related changes in antioxidant enzyme activities are region and organ, as well as sex, selective in the rat. Mech Ageing Dev 65:187–198 CrossRef
- Benzi G, Pastoris O, Marzatico F, Villa RF (1989) Cerebral enzyme antioxidant system. Influence of aging and phosphatidylcholine. J Cereb Blood Flow Metab 9:373–380 CrossRef
- McGeer PL, Itagaki S, Boyes BE, McGeer EG (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology 38:1285–1291
- Banati RB, Daniel SE, Blunt SB (1998) Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson’s disease. Mov Disord 13:221–227. doi:10.1002/mds.870130205 CrossRef
- Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F (1993) GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260:1130–1132 CrossRef
- Uchida K, Kihara N, Hashimoto K, Nakayama H, Yamaguchi R, Tateyama S (2003) Age-related histological changes in the canine substantia nigra. J Vet Med Sci 65:179–185 CrossRef
- O’Callaghan JP, Miller DB (1991) The concentration of glial fibrillary acidic protein increases with age in the mouse and rat brain. Neurobiol Aging 12:171–174 CrossRef
- Castillo-Ruiz MM, Campuzano O, Acarin L, Castellano B, Gonzalez B (2007) Delayed neurodegeneration and early astrogliosis after excitotoxicity to the aged brain. Exp Gerontol 42:343–354. doi:10.1016/j.exger.2006.10.008 CrossRef
- Ciesielska A, Joniec I, Kurkowska-Jastrzebska I, Cudna A, Przybylkowski A, Czlonkowska A, Czlonkowski A (2009) The impact of age and gender on the striatal astrocytes activation in murine model of Parkinson’s disease. Inflamm Res 58:747–753. doi:10.1007/s00011-009-0026-6 CrossRef
- Miller DB, O’Callaghan JP, Ali SF (2000) Age as a susceptibility factor in the striatal dopaminergic neurotoxicity observed in the mouse following substituted amphetamine exposure. Ann N Y Acad Sci 914:194–207 CrossRef
- Gordon MN, Schreier WA, Ou X, Holcomb LA, Morgan DG (1997) Exaggerated astrocyte reactivity after nigrostriatal deafferentation in the aged rat. J Comp Neurol 388:106–119 CrossRef
- Dluzen DE, Disshon KA, McDermott JL (1998) Estrogen as a modulator of striatal dopaminergic neurotoxicity. In: Marwah J, Teitelbaum H (eds) Advances in neurodegenerative disorders, vol 1: Parkinson’s disease. Prominent Press, Scottsdale, pp 149–192
- Lichtensteiger W (1969) Cyclic variations of catecholamine content in hypothalamic nerve cells during the estrous cycle of the rat, with a concomitant study of the substantia nigra. J Pharmacol Exp Ther 165:204–215
- Kenchappa RS, Diwakar L, Annepu J, Ravindranath V (2004) Estrogen and neuroprotection: higher constitutive expression of glutaredoxin in female mice offers protection against MPTP-mediated neurodegeneration. FASEB J 18:1102–1104
- Liu B, Dluzen DE (2007) Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson’s disease. Clin Exp Pharmacol Physiol 34:555–565 CrossRef
- Currie LJ, Harrison MB, Trugman JM, Bennett JP, Wooten GF (2004) Postmenopausal estrogen use affects risk for Parkinson disease. Arch Neurol 61:886–888 CrossRef
- Bedard P, Langelier P, Villeneuve A (1977) Oestrogens and extrapyramidal system. Lancet 2:1367–1368 CrossRef
- Koller WC, Barr A, Biary N (1982) Estrogen treatment of dyskinetic disorders. Neurology 32:547–549
About this Article
- Title
- Increased Oxidative Damage and Decreased Antioxidant Function in Aging Human Substantia Nigra Compared to Striatum: Implications for Parkinson’s Disease
- Journal
-
Neurochemical Research
Volume 37, Issue 2 , pp 358-369 - Cover Date
- 2012-02-01
- DOI
- 10.1007/s11064-011-0619-7
- Print ISSN
- 0364-3190
- Online ISSN
- 1573-6903
- Publisher
- Springer US
- Additional Links
- Topics
- Keywords
-
- Aging
- Human brain
- Substantia nigra
- Caudate nucleus
- Oxidative protein damage
- Glutathione
- Glial fibrillary acidic protein
- Parkinson’s disease
- Industry Sectors
- Authors
-
- C. Venkateshappa (1)
- G. Harish (1)
- Rajeswara Babu Mythri (1)
- Anita Mahadevan (2)
-
M. M. Srinivas Bharath
(1)
- S. K. Shankar (2)
- Author Affiliations
-
- 1. Departments of Neurochemistry, National Institute of Mental Health and Neurosciences (NIMHANS), No. 2900, Hosur Road, Bangalore, Karnataka, 560029, India
- 2. Departments of Neuropathology, National Institute of Mental Health and Neurosciences (NIMHANS), No. 2900, Hosur Road, Bangalore, Karnataka, 560029, India